The most credible voices in longevity are mostly not the most visible ones. Of the 100 people ranked in the Unfiltered Longevity 100 for 2026, 38 are working scientists whose standing rests on peer-reviewed output, institutional position and replication record rather than on audience. They are listed in full below.

Credibility and reach are close to uncorrelated in this field. The people running the trials, directing the institutes and holding the editorial positions are, with a few exceptions, not the people most readers have heard of. That gap is the most useful thing to understand about who to trust here, and it is why a ranking built on capital, science and execution produces a different list from a ranking built on followers.

The 38 most credible scientific voices in longevity

Ranked by position in the Unfiltered Longevity 100, which scores every entrant across five weighted criteria. Scientific credibility carries 20% of the total. Public profile carries 15% and is weighted lowest deliberately.

#	Name	Role	Base	L100	Score
1	George Church	Co-founder, Rejuvenate Bio	United States	6	89.0
2	Shinya Yamanaka	Senior Investigator, Gladstone Institutes	Japan	7	89.0
3	Rick Klausner	Chief Scientist, Altos Labs	United States	9	87.5
4	Felipe Sierra	Founder, Geroscience Consulting	United States	21	82.5
5	Brian Kennedy	Distinguished Professor, NUS Singapore	Singapore	25	81.5
6	Nir Barzilai	Director, Institute for Ageing Research, Albert Einstein	United States	27	81.0
7	Eric Verdin	CEO, Buck Institute	United States	29	80.0
8	Andrea Maier	Professor / Co-founder, NUS / Chi Longevity	Singapore	31	79.0
9	Jean Hebert	Lead, FRONT Programme, ARPA-H / Albert Einstein	United States	34	78.5
10	Cynthia Kenyon	VP Ageing Research, Calico	United States	35	78.0
11	James Kirkland	Professor, Mayo Clinic	United States	40	77.5
12	Steve Horvath	Principal Investigator, Altos Labs	United States	42	77.0
13	Juan Carlos Izpisúa Belmonte	Senior Principal Investigator, Altos Labs	United States	43	77.0
14	Leonard Guarente	Director, Glenn Center for Biology of Ageing Research, MIT	United States	44	77.0
15	Ana Maria Cuervo	Co-director, Einstein Institute for Aging Research	United States	47	76.5
16	Rafael de Cabo	Chief, Translational Gerontology Branch, NIA	United States	48	76.5
17	Tony Wyss-Coray	Professor / Co-founder, Stanford / Alkahest	United States	51	76.0
18	Lynne Cox	Associate Professor, University of Oxford	United Kingdom	54	76.0
19	Luigi Ferrucci	Scientific Director, National Institute on Aging	United States	55	76.0
20	Sharon Rosenzweig-Lipson	CSO, Life Biosciences	United States	59	75.0
21	Linda Partridge	Founding Director, UCL Institute of Healthy Ageing / Max Planck	United Kingdom	60	75.0
22	Maria Blasco	Director, CNIO Madrid	Spain	61	75.0
23	Valter Longo	Director, Longevity Institute, USC	United States	66	74.5
24	Joan Mannick	CMO, Altos Labs	United States	67	74.0
25	Coleen Murphy	Professor of Genomics and Molecular Biology, Princeton	United States	68	74.0
26	Morgan Levine	Vice President, Altos Labs	United States	69	74.0
27	Thomas Rando	Deputy Director, Stanford Center on Longevity	United States	70	74.0
28	Jamie Justice	Executive Director, XPRIZE Healthspan	United States	72	73.5
29	Richard Miller	Architect, Interventions Testing Program, Michigan / NIA	United States	73	73.5
30	Morten Scheibye-Knudsen	Associate Professor, University of Copenhagen	Denmark	74	73.5
31	Richard Hodes	Director, National Institute on Aging	United States	77	73.0
32	Vera Gorbunova	Co-director, Aging Research Center, University of Rochester	United States	80	73.0
33	Rozalyn Anderson	Director, Wisconsin Nathan Shock Center	United States	84	72.5
34	Andrew Scott	Principal Scientist, Ellison Institute of Technology Oxford	United Kingdom	85	72.5
35	Matt Kaeberlein	CEO / Principal Investigator, Optispan / Dog Aging Project	United States	86	72.5
36	Vadim Gladyshev	Professor, Harvard Medical School	United States	91	72.0
37	David Sinclair	Professor / Co-founder, Harvard / Life Biosciences	United States	92	72.0
38	Jennifer Garrison	Associate Professor, Buck Institute	United States	97	71.5

How credibility was assessed

Scientific credibility in the Longevity 100 is scored on peer-reviewed output, institutional standing, replication record and recognition by other scientists. It is one of five criteria, alongside capital power, strategic influence, original impact and public profile.

This page is the scientist cohort of that ranking, in composite order. It is not a re-scoring on credibility alone, and a researcher placed lower here is not less credible than one placed higher — the composite rewards capital and convening power, which many excellent scientists neither have nor want. What the list does identify reliably is the population whose standing is grounded in published work and institutional position rather than in reach.

Why the most credible voices are rarely the most followed

Longevity research is a small field. Mo Elzek, founder of the London Longevity Network, puts the global population of people actually doing the science at fewer than a thousand, and argues that a field that small does not generate enough disagreement to correct itself — a problem he describes as value locking, where an idea takes hold and successive cohorts follow it in the wrong direction. His full assessment of where the hype sits is in our interview on whether the longevity industry is legitimate.

The practical consequence is that public attention concentrates on a handful of communicators while the evidence base is produced by several hundred people most readers could not name. Neither group is the enemy of the other. But if the question is whose claims to weight, the answer is not the one the follower counts suggest.

What makes a longevity voice credible?

Six things are worth checking, and all of them are checkable in a few minutes. Whether the person publishes peer-reviewed work, or only talks about other people’s. Whether the institutional affiliation they cite is current and verifiable on the institution’s own site. Whether their findings have been replicated by a group with no connection to them. Whether they sell the thing they recommend, and whether they say so unprompted. Whether they distinguish clearly between results in mice, in cell lines and in humans, which is the single most common place longevity claims break. And whether they have ever publicly changed their mind about something, which in a field this young is a stronger signal than consistency.

Who should you follow in longevity?

That is a different question with a different answer, and the difference matters. Four of the most widely followed voices in the field are absent from the list above — Peter Attia, Rhonda Patrick, Eric Topol and Aubrey de Grey — because none of them appears in the Unfiltered Longevity 100, which ranks power over the field rather than reach into the audience. Their absence here is a function of what this list measures, not a judgement on any of them. We cover them, and the seven people in the ranking who publish regularly, in our list of longevity researchers and communicators worth following.

Frequently asked

Who is the most credible voice in longevity?

There is no single one, and any list that names one is selling something. Of the 38 working scientists in the Unfiltered Longevity 100 for 2026, the highest-placed are George Church of Harvard and Rejuvenate Bio, Shinya Yamanaka of the Gladstone Institutes, whose Nobel-recognised work on cellular reprogramming underpins much of the current field, and Rick Klausner, chief scientist at Altos Labs. Credibility in this field is distributed across an institutional population rather than held by an individual.

Are longevity influencers credible?

Some are, and the useful test is not whether they have an audience but whether their claims survive being checked against the primary literature. Three people in the Unfiltered Longevity 100 are categorised as influencers rather than scientists, founders, investors or executives, which is a reasonable indication of how small the genuinely influential communicator population is relative to the research population.

How many people work in longevity research?

Fewer than most people assume. Elzek’s estimate is under a thousand worldwide doing the actual science, which is the root of the echo-chamber problem in the field and the reason he argues it needs to be ten to a hundred times larger.

Is David Sinclair credible?

He is a tenured Harvard professor with a substantial peer-reviewed record, and he is also among the most commercially active and most publicly criticised scientists in the field. Both are true and neither settles the question. The honest position is to weight his published work on its own terms and to treat his commercial positions as commercial positions, which is the same standard that should apply to everyone on this list.